Grufity logoGrufity logo

Novavax Inc Stock Research

NVAX

5.97USD+0.07(+1.19%)Market Closed

Market Summary

USD5.97+0.07
Market Closed
1.19%

NVAX Alerts

NVAX Stock Price

NVAX RSI Chart

NVAX Valuation

Market Cap

513.7M

Price/Earnings (Trailing)

-0.78

Price/Sales (Trailing)

0.26

EV/EBITDA

1.36

Price/Free Cashflow

-1.02

NVAX Price/Sales (Trailing)

NVAX Profitability

Operating Margin

54.46%

EBT Margin

-32.98%

Return on Equity

103.76%

Return on Assets

-29.13%

Free Cashflow Yield

-98.11%

NVAX Fundamentals

NVAX Revenue

Revenue (TTM)

2.0B

Revenue Y/Y

60.85%

Revenue Q/Q

-51.35%

NVAX Earnings

Earnings (TTM)

-657.9M

Earnings Y/Y

78.46%

Earnings Q/Q

-8.09%

Price Action

52 Week Range

5.6885.60
(Low)(High)

Last 7 days

-14.4%

Last 30 days

-39.7%

Last 90 days

-47.9%

Trailing 12 Months

-92.0%

NVAX Financial Health

Current Ratio

0.69

NVAX Investor Care

Shares Dilution (1Y)

13.45%

Diluted EPS (TTM)

-8.42

Peers (Alternatives to Novavax)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
125.3B
26.3B
-2.75% 3.76%
19.12
4.76
1.32% 11.18%
99.6B
27.3B
-8.96% 41.01%
21.68
3.65
-0.09% -26.23%
58.4B
19.3B
-12.76% 1.00%
6.99
3.03
4.29% -31.47%
38.3B
10.2B
-9.67% 32.94%
12.57
3.76
-7.36% 95.80%
MID-CAP
9.1B
1.5B
-9.09% 3.35%
58.87
6.11
31.34% 72.43%
3.2B
108.5M
-21.10% -19.55%
-9.78
29.38
122.90% -12.19%
2.5B
60.9M
-18.47% -36.46%
-8.76
41.55
17.51% 22.00%
2.1B
107.9M
22.95% 67.45%
-4.29
19.27
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-14.86% -46.41%
-4.63
11.04
-70.76% -603.77%
1.1B
7.0M
-22.18% 24.65%
-7.11
158.97
131.81% -45.39%
541.9M
96.3M
-12.99% -82.24%
-1.92
5.63
72.44% -32.79%
513.7M
2.0B
-39.67% -92.01%
-0.78
0.26
72.89% 62.27%
355.3M
111.3M
-30.55% -58.78%
-1.85
3.19
0.54% -7.86%
101.4M
159.0K
-16.47% -82.96%
-0.97
637.62
-86.46% -64.56%
25.1M
-
94.03% -77.12%
-0.31
3.21
0.51% -185.61%

Financials for Novavax

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue7.3%1,981,872,0001,846,673,0001,290,940,0001,403,032,0001,146,290,000
  S&GA Expenses18.8%488,691,000411,242,000366,159,000331,160,000298,358,000
  R&D Expenses-36.3%1,235,278,0001,940,385,0002,044,283,0002,325,320,0002,534,508,000
Costs and Expenses-14.5%2,626,608,0003,072,501,0002,696,723,0002,671,684,0002,832,866,000
EBITDA51.7%-604,713,000-1,252,892,000-1,406,213,000-1,249,250,000-
EBITDA Margin55.0%-0.31-0.68-1.09-0.89-
Earnings Before Taxes49.7%-653,647,000-1,298,813,000-1,449,062,000-1,288,764,000-1,714,536,000
EBT Margin53.1%-0.33-0.70-1.12-0.92-
Interest Expenses-2.6%19,880,00020,417,00021,430,00021,164,00021,127,000
Net Income50.2%-657,939,000-1,321,974,000-1,475,792,000-1,317,624,000-1,743,751,000
Net Income Margin53.6%-0.33-0.72-1.14-0.94-
Free Cahsflow30.8%-503,944,000-728,573,000-428,649,000322,946,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-0.4%2,2592,2672,6232,8352,577
  Current Assets-3.2%1,7031,7602,1362,3472,155
    Cash Equivalents4.4%1,3371,2811,3761,5711,515
  Inventory-55.5%37.0082.002561079.00
  Net PPE15.2%294256255247226
  Goodwill7.5%126118123131131
Liabilities2.1%2,8932,8333,0402,7702,928
  Current Liabilities47.5%2,4601,6682,1562,2612,390
Shareholder's Equity-1070.7%-63465.00-351--
  Retained Earnings-4.5%-4,275-4,093-3,925-3,414-3,617
  Additional Paid-In Capital2.7%3,7383,6413,6053,5663,352
Accumulated Depreciation-30.00----
Shares Outstanding9.6%86.0078.0078.0078.0076.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations35.1%-415-640-743-428323
  Share Based Compensation-3.3%130135148163184
Cashflow From Investing-6.5%-92.98-87.28-69.96-58.28100
Cashflow From Financing346.2%32573.0088.0045.00462

Risks for NVAX

What is the probability of a big loss on NVAX?

100%


Probability that Novavax stock will be more than 20% underwater in next one year

100%


Probability that Novavax stock will be more than 30% underwater in next one year.

95.8%


Probability that Novavax stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NVAX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Novavax was unfortunately bought at previous high price.

Drawdowns

Returns for NVAX

Cumulative Returns on NVAX

-17.8%


10-Year Cumulative Returns

-33.0%


7-Year Cumulative Returns

-32.8%


5-Year Cumulative Returns

-11.1%


3-Year Cumulative Returns

What are the long-term rolling returns for NVAX?

FIve years rolling returns for Novavax.

Annualized Returns

Which funds bought or sold NVAX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
-664
1,336
-%
2023-03-06
Rockefeller Capital Management L.P.
unchanged
-
-11,000
13,000
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
unchanged
-
154
154
-%
2023-02-28
Voya Investment Management LLC
reduced
-1.38
-557,575
701,425
-%
2023-02-24
NATIXIS
sold off
-100
-7,856,000
-
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-
-16,000
-
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
21.56
-2,465
7,535
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
reduced
-41.18
-20,327
2,673
-%
2023-02-16
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
new
-
1,623
1,623
-%
2023-02-15
Bridgefront Capital, LLC
new
-
108,690
108,690
0.08%

1–10 of 44

Latest Funds Activity

Are funds buying NVAX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own NVAX
No. of Funds

Novavax News

Marketscreener.com

A Company With Solutions Against Emerging COVID Variants And ....

Marketscreener.com,
6 hours ago

Investor's Business Daily

The Motley Fool

The Motley Fool

Novavax Stock: Bear vs. Bull.

The Motley Fool,
10 days ago

Investor's Business Daily

The Motley Fool

Why Novavax Stock Wilted on Wednesday.

The Motley Fool,
26 days ago

The Motley Fool

The Motley Fool

Schedule 13G FIlings of Novavax

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
10.41%
8,844,653
SC 13G/A
Feb 02, 2023
state street corp
7.15%
6,076,518
SC 13G/A
Feb 01, 2023
blackrock inc.
5.7%
4,808,261
SC 13G/A
Mar 11, 2022
blackrock inc.
5.8%
4,410,761
SC 13G/A
Feb 14, 2022
ra capital management, l.p.
2.8%
2,097,794
SC 13G/A
Feb 08, 2022
blackrock inc.
5.8%
4,410,761
SC 13G
Feb 16, 2021
d. e. shaw & co, l.p.
0.2%
110,645
SC 13G/A
Feb 16, 2021
ra capital management, l.p.
6.0%
3,788,564
SC 13G
Feb 10, 2021
vanguard group inc
8.79%
5,598,760
SC 13G
Feb 05, 2021
blackrock inc.
8.1%
5,137,631
SC 13G/A

NVAX Fair Value

Novavax fair value in different scenarios

The table shows the Fair Value estimates for Novavax for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

2.20

-63.15%

21.52

260.47%

53.46

795.48%

116.83

1856.95%
Current Inflation

-

-

1.33

-77.72%

18.33

207.04%

45.97

670.02%

100.50

1583.42%
Very High Inflation

-

-

0.27

-95.48%

14.51

143.05%

37.13

521.94%

81.41

1263.65%

Historical Novavax Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Novavax

View All Filings
Date Filed Form Type Document
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
8-K
Current Report
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
3
Insider Trading

Latest Insider Trading transactions for NVAX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-10
Kelly James Patrick
sold (taxes)
-16,110
6.52
-2,471
evp, cfo and treasurer
2023-03-10
Kelly James Patrick
acquired
30,050
6.52
4,609
evp, cfo and treasurer
2023-03-10
Trizzino John
sold (taxes)
-16,110
6.52
-2,471
evp, cco and cbo
2023-03-10
Herrmann John A III
acquired
30,050
6.52
4,609
evp, chief legal officer
2023-03-10
Glenn Gregory M
sold (taxes)
-15,856
6.52
-2,432
president, r&d
2023-03-10
Glenn Gregory M
bought
6,500
6.5
1,000
president, r&d
2023-03-10
Trizzino John
acquired
30,050
6.52
4,609
evp, cco and cbo
2023-03-10
Glenn Gregory M
acquired
41,063
6.52
6,298
president, r&d
2023-03-10
Herrmann John A III
sold (taxes)
-11,605
6.52
-1,780
evp, chief legal officer
2023-03-07
Glenn Gregory M
bought
14,088
7.044
2,000
president, r&d

1–10 of 50

About Novavax

NVAX Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Revenues$ 1,981,872,000$ 1,146,290,000$ 475,598,000
Expenses:   
Cost of sales902,639,00000
Research and development1,235,278,0002,534,508,000747,027,000
Selling, general, and administrative488,691,000298,358,000145,290,000
Total expenses2,626,608,0002,832,866,000892,317,000
Loss from operations(644,736,000)(1,686,576,000)(416,719,000)
Other income (expense):   
Interest expense(19,880,000)(21,127,000)(15,145,000)
Other income (expense)10,969,000(6,833,000)13,605,000
Loss before income tax expense(653,647,000)(1,714,536,000)(418,259,000)
Income tax expense4,292,00029,215,0000
Net loss$ (657,939,000)$ (1,743,751,000)$ (418,259,000)
Net loss per share:   
Basic (in usd per share)$ (8.42)$ (23.44)$ (7.27)
Diluted (in usd per share)$ (8.42)$ (23.44)$ (7.27)
Weighted average number of common shares outstanding:   
Basic (in shares)78,18374,40057,554
Diluted (in shares)78,18374,40057,554
Product sales   
Revenue:   
Revenues$ 1,554,961,000$ 0$ 0
Grants   
Revenue:   
Revenues382,921,000948,709,000453,210,000
Royalties and other   
Revenue:   
Revenues$ 43,990,000$ 197,581,000$ 22,388,000

NVAX Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 1,336,883,000$ 1,515,116,000
Restricted cash10,303,00011,490,000
Accounts receivable82,375,000454,993,000
Inventory36,683,0008,872,000
Prepaid expenses and other current assets237,147,000164,648,000
Total current assets1,703,391,0002,155,119,000
Property and equipment, net294,247,000225,741,000
Total non-current ROU assets106,241,00040,123,000
Goodwill126,331,000131,479,000
Other non-current assets28,469,00024,291,000
Total assets2,258,679,0002,576,753,000
Current liabilities:  
Accounts payable216,517,000127,050,000
Accrued expenses591,158,000673,731,000
Deferred revenue370,137,0001,422,944,000
Current portion of finance lease liabilities27,196,000130,533,000
Convertible notes payable324,881,0000
Other current liabilities930,055,00036,061,000
Total current liabilities2,459,944,0002,390,319,000
Deferred revenue179,414,000172,528,000
Convertible notes payable166,466,000323,458,000
Non-current portion of finance lease liabilities31,238,0000
Other non-current liabilities55,695,00042,121,000
Total liabilities2,892,757,0002,928,426,000
Commitments and contingencies (Note 18)
Preferred stock, $0.01 par value, 2,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 202100
Stockholders’ equity (deficit):  
Common stock, $0.01 par value, 600,000,000 shares authorized at December 31, 2022 and 2021; and 86,806,554 shares issued and 86,039,923 shares outstanding at December 31, 2022 and 76,433,151 shares issued and 75,841,171 shares outstanding at December 31, 2021868,000764,000
Additional paid-in capital3,737,979,0003,351,967,000
Accumulated deficit(4,275,889,000)(3,617,950,000)
Treasury stock, 766,631 shares, cost basis at December 31, 2022 and 591,980 shares, cost basis at December 31, 2021(90,659,000)(85,101,000)
Accumulated other comprehensive loss(6,377,000)(1,353,000)
Total stockholders’ equity (deficit)(634,078,000)(351,673,000)
Total liabilities and stockholders’ equity (deficit)$ 2,258,679,000$ 2,576,753,000